Literature DB >> 11791944

Color Doppler imaging of retrobulbar hemodynamics after topical carteolol in normal tension glaucoma.

M J Chen1, J Ching, K Chou, H J Chiou, W M Hsu.   

Abstract

BACKGROUND: Carteolol is a nonselective adrenergic blocking agent. The aim of this study was to evaluate the effect of topical carteolol on retrobulbar hemodynamics in patients with normal tension glaucoma (NTG).
METHODS: Twelve NTG patients received twelve-week topical treatment of 2% carteolol. Color Doppler imaging (CDI) was used to evaluate the hemodynamic effects before and after drug therapy. Measurements were obtained from the central retinal artery (CRA), the lateral posterior ciliary artery (LPCA) and the medial posterior ciliary artery (MPCA). From each vessel, peak systolic velocity (PSV), end-diastolic velocity (EDV), resistance index (RI) and Gosling's pulsatility index (PI) were collected and analyzed.
RESULTS: After topical carteolol treatment for twelve weeks, mean resistance index reduced significantly from 0.83 to 0.74 in the CRA (p = 0.03), from 0.74 to 0.68 in the LPCA (p = 0.09). Moreover, mean pulsatility index of the LPCA decreased from 1.45 to 1.26 (p = 0.08).
CONCLUSIONS: Twelve weeks of 2% carteoiol treatment may decrease the vascular resistance in NTG patients possibly due to the intrinsic sympathomimetic activity (ISA) of carteolol.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11791944

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi (Taipei)        ISSN: 0578-1337


  2 in total

1.  Effect of carteolol hydrochloride on 24-hour variation of intraocular pressure in normal-tension glaucoma.

Authors:  Kenji Nakamoto; Noriko Yasuda
Journal:  Jpn J Ophthalmol       Date:  2010-04-18       Impact factor: 2.447

Review 2.  Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension.

Authors:  Sheridan Henness; Tracy Swainston Harrison; Gillian M Keating
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.